A radical attack on prostate cancer
By Matthew Herper | Thursday, May 29, 2007 | Forbes.com
Seattle-based biotech company Dendreon is marketing a new concept in cancer prevention. Provenge is a therapeutic antibody against prostate cancer that is customized for each patient to utilize that individual’s immune “signature” to avoid rejection and to give that person’s individualized immune system the right tools for the job…BS
http://www.forbes.com/2007/03/28/prostate-cancer-treatment-biz-cx_mh_0328prostate_print.html
This entry was posted on Thursday, March 29th, 2007 at 3:36 AM and filed under Health, Science. Follow comments here with the RSS 2.0 feed. Skip to the end and leave a response. Trackbacks are closed.
